Apotex's U.S. Business Lags in Public Debut Amid Heightened Competition, Plant Pause -- Market Talk
Dow Jones2026/08/12 19:11Apotex's U.S. segment is a weak spot in its public market debut, as increased market competition and an operational plant pause weigh on revenue. Excluding last year's generic revlimid windfall, underlying U.S. sales slipped 8.6% to C$362.9 million, with the drop worsening to a steep 48.5% on a reported basis. Apotex cites fresh competition following lost exclusivities on key drugs including leukemia treatment nilotinib, alongside a temporary halt on U.S.-bound eye drop shipments for Richmond Hill plant remediation. CEO Jeff Watson says on the earnings call that the company expects to be ready for FDA re-inspection by the end of the calendar year. The U.S. performance contrasts with Canada's 11.5% sales rise. Shares are down 4.2% to C$35.13. (adriano.marchese@wsj.com)
(END) Dow Jones Newswires
August 12, 2026 15:11 ET (19:11 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-IIFL Finance rallies to a two-month high, boosted by Blackstone deal
The “outlier” in the AI capital expenditure frenzy: Apple (AAPL.US) keeps spending flat, accounting for less than 5% of sales
Apple continues to stand out among major tech peers, largely avoiding the aggressive wave of capital expenditure associated with artificial intelligence (AI) infrastructure.
Youth Employment Declines for 48 Consecutive Months: Behind the Semiconductor Boom, Young South Koreans Are Being Left Behind by the Times
In South Korea, the unemployment rate in October fell to a three-year low of 2.5%. However, the number of employed people decreased by 50,000, youth employment has declined for 48 consecutive months, and domestic demand remains weak.
Crypto prices
More
